Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe.
Brobert G, Ruigomez A, Schink T, Voss A, Herings R, Smits E, Swart KMA, Friberg L, Balabanova Y, Tarenz C, Suzart-Woischnik K, Soriano-Gabarró M, Vora P, Homering M, Dyszynski T, Nagel G, Amaya P, García Rodríguez LA. Brobert G, et al. Among authors: herings r. BMJ Open. 2024 Mar 25;14(3):e081348. doi: 10.1136/bmjopen-2023-081348. BMJ Open. 2024. PMID: 38531587 Free PMC article. Review.
Development Of A Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (Pass) Programme Examining Rivaroxaban Use In Routine Clinical Practice.
Brobert G, García RL, Garbe E, Bezemer ID, Layton D, Friberg L, Suzart-Woischnik K, Alderson J, Winchester C, Herings RM, Jobski K, Schink T, Shakir S, Soriano-Gabarró M, Wallander MA. Brobert G, et al. Among authors: herings rm. Value Health. 2014 Nov;17(7):A473-4. doi: 10.1016/j.jval.2014.08.1350. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201360 Free article. No abstract available.
Thrombotic risk minimization for Diane-35 and generics.
Bezemer ID, Smits E, Penning-van Beest FJA, Asiimwe A, Herings RMC. Bezemer ID, et al. Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1411-1417. doi: 10.1002/pds.4319. Epub 2017 Sep 26. Pharmacoepidemiol Drug Saf. 2017. PMID: 28952198
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis.
Morales DR, Morant SV, MacDonald TM, Hallas J, Ernst MT, Pottegard A, Herings RMC, Smits E, Overbeek JA, Mackenzie IS, Doney ASF, Mitchell L, Bennie M, Robertson C, Wei L, Nicholson L, Morris C, Flynn RWV. Morales DR, et al. Among authors: herings rmc. Br J Clin Pharmacol. 2021 Mar;87(3):1129-1140. doi: 10.1111/bcp.14478. Epub 2020 Aug 2. Br J Clin Pharmacol. 2021. PMID: 32668021 Free article.
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice.
García-Rodríguez LA, Wallander MA, Friberg L, Ruigomez A, Schink T, Bezemer I, Herings R, Shakir S, Evans A, Davies M, Suzart-Woischnik K, Vora P, Balabanova Y, Soriano-Gabarró M, Brobert G. García-Rodríguez LA, et al. Among authors: herings r. Expert Opin Drug Saf. 2020 Nov;19(11):1513-1520. doi: 10.1080/14740338.2020.1798928. Epub 2020 Aug 4. Expert Opin Drug Saf. 2020. PMID: 32700977
275 results